This annual lecture honors the legacy of Dr. Bruce Hasegawa. MILabs’ Founder and CEO, Prof. Freek Beekman, presents the 2021 Bruce Hasegawa Memorial Lecture at the University of California, San Francisco. In this video presentation, he talks about the physics, engineering, and application of Fully Integrated Ultra-High Definition Optical Tomography, PET, SPECT & X-ray CT.
This webinar covers some recent groundbreaking studies conducted by the Cornelissen group in Oxford. Several recent papers will be presented including ‘Early detection in a mouse model of pancreatic cancer by imaging DNA damage response signaling’, ‘Dual-isotope antibody imaging allows in vivo immunohistochemistry using radiolabelled antibodies in tumours’, and ‘Imaging DNA Damage Repair in vivo Following 177Lu-DOTATATE Therapy’.
Marko Rosenholm presents some of the findings and results regarding dynamic SPECT/CT imaging of a glymphatic system they have acquired with the MILabs VECTor/CT system.
This talk describes the extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy. In vivo imaging was performed on the MILabs VECTorCT imaging platform.
Each DNA damage repair pathway leads to the recruitment, upregulation, or activation of specific proteins within the nucleus, which, in some cases, can represent attractive targets for molecular imaging.
Implant-associated infections such as periprosthetic joint infections are difficult to treat as the bacteria form a biofilm on the prosthetic material. In this webinar, Prof. Van der Wal shows the possibilities of radioimmunotherapy for non-invasive treatment of implant associated infections.
Exploit simultaneous 99mTc-HSA/64Cu-ATSM imaging to accelerate the development of 64Cu-ATSM as an add-on targeted radiotherapy agent.
This webinar describes the key applications of nuclear imaging in immuno-oncology. Currently, numerous immuno-oncological drugs are being developed to treat cancer patients. However, many questions remain unanswered, such as how, when, and for whom this treatment is most effective.
This webinar highlights the potency of 212Pb-alpha radioimmunotherapy in Multiple Myeloma treatment. The results of this study showed the efficacy of 212Pb-daratumumab in xenografted mice with significant tumor regression and increased survival.
This webinar highlights some of the key imaging applications at the UBC such as theranostic α-emitters imaging (e.g. 225Ac and 211At), nanomedicine, quantitative imaging of novel dual-isotope combinations, such as 111In and 67Ga, investigations of mechanisms of delivery and pharmacokinetics of antibiotics and antimicrobials, investigation of metal chelators and their use as radiopharmaceuticals, studies in immunology and vaccines, and macromolecular conjugates and lipid-based formulations.
Radioimmunoimaging and radioimmunotherapy applications are supported by the MILabs VECTorCT platform at the University of Saskatchewan.
Musculoskeletal imaging plays a major role in disease diagnosis, pathogenesis, and (radio) pharmaceutics development.
In this webinar, examples of advanced imaging techniques performed on MILabs’ multimodality PET, SPECT, CT, and OI systems are presented.
Dopaminergic system is involved in many behavioral and cognitive functions and appears more and more implicated in neurological diseases. The U-SPECT imaging system allows us to estimate both the density and the affinity of dopaminergic receptors in the striatum and also in the SN/VTA.
The webinar provides an overview of the key role of SPECT/CT imaging on osteoarthritis and rheumatoid arthritis research in small animals.
This talk describes the most recent advances of the award-winning MILabs VECTor6 PET, SPECT, X-ray & Optical CT preclinical imaging platform. Several unique applications of the VECTor 6 technology will be presented, performed by many research labs across the globe.
